Fig. 6.

SRT1720 alleviated TAM-induced hepatic steatosis by inhibiting p-FoxO1/LXRα-SREBP1c pathway. The protein expressions of p-FoxO1/FoxO1, p-AMPK/AMPK and LXRα were investigated by western blot. Band intensity was quantified by densitometry analysis. The rats were treated with TAM (8 mg/kg) or TAM combined with SRT1720 (15 or 30 mg/kg) after 15 weeks of HFD. The data are the mean ± SEM (n = 6). ^*P < 0.05, ^***P < 0.001 compared to the control group. ^#P < 0.05, ^##P < 0.01, ^###P < 0.001 compared to the TAM treatment group.